Phreesia (PHR) Insider Ramin Sayar Buys $185K of Stock
Phreesia saw a flurry of insider buying on June 24, 2026, including a purchase by Ramin Sayar.
Reviewed by automated data checks against the source filing. How we make and check alerts
Ramin Sayar bought 19,290 shares of Phreesia, Inc. ($PHR) at an average price of $9.59, worth about $184,991.10, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PHR is up 11.8% after 1 week, up 6.6% after 1 month and up 14.1% to date (from the $9.59 close on Jun 24, 2026).
PHR
Phreesia, Inc.
Key Points
- Ramin Sayar purchased 19,290 shares of Phreesia, Inc. (NYSE:PHR) at a price of $9.59 per share on June 24, 2026.
- The stock trades closer to its 52-week low of $7.77 rather than its high of $25.00 ahead of its December earnings report.
- Wall Street analysts currently maintain a consensus buy rating on the stock with a mean price target of $13.94.
Get $PHR trade alerts by text
We text you when insiders, Congress or big funds trade $PHR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Phreesia, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Phreesia, Inc.
Ramin Sayar purchased 19,290 shares of Phreesia, Inc. (NYSE:PHR) on June 24, 2026, according to an SEC filing. The shares were bought at $9.59 each, for a total transaction value of roughly $184,991. This trade formed part of a coordinated wave of purchases executed by several insiders on the exact same date at the identical price.
Recent Insider Activity
Jon Kessler, Gillian Munson, Lisa Egbuonu-Davis, Smith Mark Douglas, and Lainie Goldstein each purchased 19,290 shares of Phreesia, Inc. at $9.59 apiece on June 24, 2026. Each of these transactions totaled about $184,991, bringing the group's collective acquisition activity into sharp focus for market observers tracking executive sentiment.
Phreesia Stock Valuation
The shares recently changed hands at $9.13, moving within a 52-week range spanning from $7.77 to $25.00. The company carries a market capitalization of roughly $622.57 million and a beta of 0.86, pointing to steadier price action relative to the broader market.
Analysts Set New Price Targets
Wall Street firms maintain varied stances on the stock, backed by a consensus recommendation of buy and a mean price target of $13.94 across 16 analyst opinions. On October 12, 2026, Barclays maintains its Equal-Weight rating with an 11.00 price target. Earlier in the autumn, Raymond James issued a downgrade to a Market Perform rating on September 8, 2026. DA Davidson maintains its Buy rating with a 13.00 price target on September 4, 2026. Baird maintains its Neutral rating with an 11.00 price target on September 4, 2026. Freedom Capital Markets maintains its Buy rating with a 14.00 price target on September 3, 2026. RBC Capital reiterates its Outperform rating with a 19.00 price target on September 3, 2026. Wells Fargo maintains its Equal-Weight rating with a 10.00 price target on September 3, 2026. Canaccord Genuity maintains its Buy rating with a 16.00 price target on September 3, 2026.
About the Company
Phreesia operates an integrated software and payment platform designed for the healthcare sector, helping medical providers streamline patient intake, administrative workflows, and digital communication across the United States and Canada.
What's Ahead for PHR
Investors are now turning their attention toward Phreesia's next earnings report scheduled for December 7, 2026, for further details on revenue growth and profit margins. Insider transactions provide a look at executive sentiment but represent only one piece of a broader financial puzzle.
Related Filing Alerts
Source: Ramin Sayar's Form 4 filing on $PHR (Jun 24, 2026). Find the original filing: PHR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts